Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.

NCT01268358 is registered in ClinicalTrials.gov with Zymenex A/S as lead sponsor.

NCT NCT01268358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01268358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.
Lead sponsor
Zymenex A/S
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
January 31, 2011
Enrollment
10 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alpha mannosidosis